Serum IGF1 Is a Prognostic Marker for Resistance to Targeted Therapies and a Predictive Marker for Anti-IGF1 Receptor Therapy in Melanoma

Affiliations

• ¹ Institute for Advanced Biosciences, INSERM U1209, CNRS UMR5309, Grenoble Alpes University, Grenoble, France; École Pratique des Hautes Études, PSL Research University, Paris, France.
• ² Institute for Advanced Biosciences, INSERM U1209, CNRS UMR5309, Grenoble Alpes University, Grenoble, France; Dermatology, Allergology & Photobiology Department, Grenoble Alpes University Hospital, Grenoble Alpes University, Grenoble, France.
• ³ Institute for Advanced Biosciences, INSERM U1209, CNRS UMR5309, Grenoble Alpes University, Grenoble, France.
• ⁴ Dermatology, Allergology & Photobiology Department, Grenoble Alpes University Hospital, Grenoble Alpes University, Grenoble, France.
• ⁵ Biology and Pathology Institute, Grenoble Alpes University Hospital, Grenoble Alpes University, Grenoble, France.
• ⁶ Institute for Advanced Biosciences, INSERM U1209, CNRS UMR5309, Grenoble Alpes University, Grenoble, France. Electronic address: amandine.hurbin@inserm.fr.